STAT+ highlights growing safety concerns for radiopharmaceutical developers as more programs move into clinical trials. While the targeting premise remains that isotopes can deliver radiation more selectively to tumors than conventional external-beam therapy, the report says adverse radiation exposure to organs like kidneys, liver, and bone marrow is emerging as a recurring problem. The story frames the issue around the biological behavior of radiopharmaceutical isotopes: even when attached to tumor-seeking molecules, the pharmacology and biodistribution can still put non-target tissues at risk. That creates added complexity in dose selection, patient monitoring, and risk-benefit positioning. For the field, the near-term consequence is that tolerability and organ-specific radiation exposure may increasingly determine which candidates can progress and how trials are designed.